I
Ionis Pharmaceuticals, Inc. (IONS)
NMS – Real vaqt narxi. Valyuta: USD
72.15
-2.09 (-2.82%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
72.15
0.00 (0.00%)
Bozordan keyin: Mar 27, 2026, 4:34 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
NMS – Real vaqt narxi. Valyuta: USD
72.15
-2.09 (-2.82%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
72.15
0.00 (0.00%)
Bozordan keyin: Mar 27, 2026, 4:34 PM EDT
Ionis Pharmaceuticals, Inc., tijorat bosqichidagi biotexnologiya kompaniyasi, Qo'shma Shtatlarda RNKga yo'naltirilgan dorilarni taqdim etadi. Kompaniya kattalar uchun oilaviy xilomikronemiya sindromi (FCS) va o'tkir pankreatitda triglitseridlar darajasini pasaytiradigan TRYNGOLZA; kattalar uchun irsiy angionevrotik shishning hujumlarini oldini olish uchun DAWNZERA; kattalar uchun irsiy transtiretin-mediatsiyalangan amiloidoz (ATTRv-PN) polinevropatiyasini davolash uchun WAINUA; va bolalar va kattalar uchun spinal mushak atrofiyasi (SMA) bilan og'rigan bemorlar uchun SPINRAZA ni taklif etadi. U, shuningdek, O'tkir Lateral Skleroz (ALS) ni davolash uchun QALSODY; kattalar uchun ATTRv-PN ni davolash uchun TEGSEDI; va FCS va oilaviy qisman lipodistrofiya uchun WAYLIVRA ni taqdim etadi. Kompaniya, shuningdek, gipertriglitseridemiya (SHTG) va yurak-qon tomir kasalliklari (CVD) bo'lgan bemorlar uchun Olezarsen; va genetik tasdiqlangan Aleksandr kasalligi bo'lgan odamlar uchun potentsial davolash bo'lgan Zilganerse, shuningdek, AS, noyob genetik nevrologik kasallikni potentsial davolash uchun 3-bosqich klinik sinovida bo'lgan ION582 kabi 3-bosqich klinik sinovlari ostidagi mahsulotlarni ishlab chiqadi. Bundan tashqari, kompaniya TTR mRNAga bog'lanish orqali mutatsiyaga uchragan va yovvoyi turdagi TTR mRNAni parchalash uchun Eplontersen; jigarda apolipoprotein(a) ishlab chiqarishni inhibe qilish orqali lipoprotein(a)ni kamaytirish uchun to'g'ridan-to'g'ri yondashuvni taklif qiluvchi Pelacarsen; gepatit B virusi bilan bog'liq virusli oqsillar ishlab chiqarishni inhibe qiluvchi Bepirovirsen; komplement omili B ishlab chiqarishni kamaytirish va alternativ komplement yo'lining faollashuvini pasaytirish uchun Sefaxersen; va sarkomada birlashgan oqsil ishlab chiqarishni kamaytirish uchun Ulefnersen, shuningdek, boshqa o'rta bosqichli quvur liniyasi tadqiqot dorilarini ishlab chiqadi. U nevrologik kasalliklarni davolash bo'yicha Biogen bilan strategik hamkorlikka ega; va GSK, AstraZeneca, Novartis va Roche, shuningdek, Metagenomi bilan hamkorlik va litsenziyalash shartnomalariga ega. Kompaniya 1989 yilda ro'yxatga olingan va uning bosh qarorgohi Kaliforniyaning Carlsbad shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Brett P. Monia Ph.D. | Founder, CEO & Director |
| Dr. C. Frank Bennett BSc, Ph.D. | Executive VP & Chief Scientific Officer |
| Dr. Eugene Schneider M.D. | Executive VP, Chief Clinical Development & Operations Officer |
| Dr. Richard S. Geary Ph.D. | Strategic Consultant |
| Mr. D. Wade Walke Ph.D. | Senior Vice President of Investor Relations |
| Mr. Darren Gonzales | Chief Accounting Officer & Senior VP |
| Mr. Kyle Jenne | Executive VP & Chief Global Product Strategy Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-09 | 8-K | ef20067398_8k.htm |
| 2026-01-12 | 8-K | ef20062670_8k.htm |
| 2026-01-07 | 8-K | ef20062477_8k.htm |
| 2025-11-17 | 8-K | d31230d8k.htm |
| 2025-11-10 | 8-K | ef20058520_8k.htm |
| 2025-11-03 | 8-K/A | ef20058178_8ka.htm |
| 2025-10-29 | 10-Q | form10q.htm |
| 2025-09-22 | 8-K | ef20055880_8k.htm |
| 2025-09-02 | 8-K | ef20054942_8k.htm |
| 2025-08-21 | 8-K | ef20054334_8k.htm |
| Mr. Patrick R. O'Neil Esq. | Executive VP, Chief Legal Officer, General Counsel & Corporate Secretary |
| Ms. Elizabeth L. Hougen M.A., M.B.A., M.S. | Executive VP of Finance & CFO |
| Ms. Tracy Berns J.D. | Senior VP and Chief Compliance & Quality Assurance Officer |